Evidence map›Paper›PMID 28851055›Full record

Trial reportActa psychiatrica Scandinavica2017

The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.

X Fan, X Song, M Zhao, L F Jarskog, R Natarajan, N Shukair, O Freudenreich, D C Henderson, D C Goff

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Acta psychiatrica Scandinavica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Analysis of clinical studies on clozapine from 2012-2022.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

X FanPsychotic Disorders Program, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA, USA.ORCID 0000-0003-4299-8924
X SongDepartment of Psychiatry, The1st Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
M ZhaoShanghai Mental Health Center, Shanghai, China.
L F JarskogDepartment of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
R NatarajanPsychotic Disorders Program, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA, USA.
N ShukairPsychotic Disorders Program, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA, USA.
O FreudenreichSchizophrenia Program, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
D C HendersonDepartment of Psychiatry, Boston University/Boston Medical Center, Boston, MA, USA.
D C GoffDepartment of Psychiatry, New York University Medical School and Nathan Kline Institute, New York, NY, USA.
University of Massachusetts Chan Medical School · USBoston University · USHarvard University · USNathan Kline Institute for Psychiatric Research · USShanghai Mental Health Center · CNUniversity of North Carolina at Chapel Hill · USZhengzhou University · CN

Funding

Innovative Intervention Strategies for Metabolic Problems in SchizophreniaK23MH082098 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FAN, XIAODUO · 2008 to 2012
$926k
NIMH NIH HHS K23 MH082098
6 · The paper itself

Abstract

objectiveThis study examined the effect of adjunctive telmisartan on psychopathology and cognition in olanzapine- or clozapine-treated patients with schizophrenia.

methodIn a 12-week randomized, double-blind, placebo-controlled study, patients diagnosed with schizophrenia or schizoaffective disorder received either telmisartan (80 mg once per day) or placebo. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS) and the Scale for Assessment of Negative Symptoms (SANS), and a neuropsychological battery was used to assess cognitive performance. Assessments for psychopathology and cognition were conducted at baseline and week 12.

resultsFifty-four subjects were randomized, and 43 completed the study (22 in the telmisartan group, 21 in the placebo group). After 12-weeks of treatment, the telmisartan group had a significant decrease in PANSS total score compared withthe placebo group (mean ± SD: - 4.1 ± 8.1 vs. 0.4 ± 7.5, P = 0.038, SCohen's d = 0.57). There were no significant differences between the two groups in change from baseline to week 12 in PANSS subscale scores, SANS total score, or any cognitive measures (P > 0.100).

conclusionThe present study suggests that adjunctive treatment with telmisartan may improve schizophrenia symptoms. Future trials with larger sample sizes and longer treatment durations are warranted.

Indexed as

Outcome Assessment, Health CareAdultAngiotensin II Type 1 Receptor BlockersAntipsychotic AgentsBenzimidazolesBenzoatesBenzodiazepinesClozapineDouble-Blind MethodDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleMiddle AgedOlanzapineAngiotensin II Type 1 Receptor BlockersAntipsychotic AgentsBenzimidazolesBenzoatesBenzodiazepinesClozapineOlanzapineTelmisartancognitionpsychopathologypsychopharmacologySchizophrenia

Identifiers

PMID28851055
PMCPMC5630515
OpenAlexW2751432837

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.